Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates

Group 1 - Celldex Therapeutics reported a quarterly loss of $0.71 per share, which was better than the Zacks Consensus Estimate of a loss of $0.75, but worse than the loss of $0.57 per share from a year ago, indicating a 24.56% increase in loss year-over-year [1] - The company posted revenues of $1.18 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 24.19%, and down from $4.13 million in the same quarter last year [2] - Celldex shares have declined approximately 18.4% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.65 on revenues of $1.3 million, and for the current fiscal year, it is -$3.32 on revenues of $7.5 million [7] - The Medical - Biomedical and Genetics industry, to which Celldex belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]